MedDataX Logo

Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto

NCT ID: NCT00327639

Last Updated: 2006-05-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Treatment of patients with beta thalassemia in North America has altered dramatically during the past 40 years, with improvements in transfusion therapy and introduction of iron chelation therapy. Thalassemia patients now enjoy an increased life expectancy to the fifth and sixth decades of life, with fertility and childbearing becoming important issues. Data regarding this important topic remain limited, without clear data regarding iron control including serial assessment of hepatic iron concentration, the need for assistance in becoming pregnant, and use of iron chelating agents during pregnancy. As the life expectancy increases and overall health improves in thalassemia, clear data on fertility, pregnancy complications, and the effect of pregnancy on maternal health in thalassemia patients are necessary since these will have a direct impact on patient care, quality of life, and patient expectations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thalassemia Fertility Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

DEFINED_POPULATION

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Thalassemia, thalassemia intermedia or E-thalassemia patients in Toronto
* Subject has attempted conception

Exclusion Criteria

* Subject has any other form of blood disease
* Subject has not attempted conception
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Health Network, Toronto

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nancy F Olivieri, MD

Role: PRINCIPAL_INVESTIGATOR

University Health Network, Toronto General Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Health Network, Toronto General Hospital

Toronto, Ontario, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anthony Apostoli, B.Sc.

Role: CONTACT

[email protected]
416-340-4800 ext. 6069

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Valerie M Joseph

Role: primary

[email protected]
416-340-4800 ext. 6507

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

00000

Identifier Type: -

Identifier Source: org_study_id